Why Lineage Cell Therapeutics, Inc.’s (LCTX) Stock Is Down 6.01%
As of Wednesday, September 23, Lineage Cell Therapeutics, Inc.’s LCTX share price has dipped by 6.01%, which has investors questioning if this is right time to buy.Michael Rose
Stock Evaluator: Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. LCTX
$0.96
-0.08
-8.01%
September 23, 2026 4:00:00 PM
EST
Volume: 2,630,213
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
AMEX | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company is developing RND1, a novel hypoimmune induced pluripotent stem cell line for the development of a cell transplant candidate for the potential treatment of an undisclosed indication, as well as engages in the research and development of ILT1, an allogeneic cell transplant for the treatment of Type 1 Diabetes; and LCT-CON, an allogeneic cell transplant, as well as therapeutic products for retinal diseases, neurological diseases, ophthalmology, metabolic, and disorders and oncology. The company has a collaboration agreement with William Demant Invest for the preclinical development of ReSonance (ANP1). It also has a strategic collaboration with Factor Bioscience Inc. for the development of genetically engineered iPSC line for the company to utilize for differentiation into certain cell transplant product candidates. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Commentary & Analysis
Why Lineage Cell Therapeutics, Inc.’s (LCTX) Stock Is Up 5.19%
As of Wednesday, September 16, Lineage Cell Therapeutics, Inc.’s LCTX share price has surged by 5.19%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Lineage Cell Therapeutics, Inc.’s (LCTX) Stock Is Up 5.56%
As of Tuesday, September 08, Lineage Cell Therapeutics, Inc.’s LCTX share price has surged by 5.56%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Lineage Cell Therapeutics, Inc.’s (LCTX) Stock Is Up 6.13%
As of Wednesday, August 19, Lineage Cell Therapeutics, Inc.’s LCTX share price has surged by 6.13%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Lineage Cell Therapeutics, Inc.’s (LCTX) Stock Is Up 5.19%
As of Thursday, July 30, Lineage Cell Therapeutics, Inc.’s LCTX share price has surged by 5.19%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $263.0 | $271.9 | 30% |
|
| Shares Out (Mil) | 261.5 | 54.2 | 81% |
|
| Institutional Ownership | 85.3% | 92.9% | 53% |
|
| Float (Mil) | 190.9 | 42.1 | 73% |
|
| Beta | 1.55 | 0.95 | 84% |
|
| Avg Daily Volume (000s) | 1,404 | 612 | 75% |
|
| Price Change (52-week) |
(32.0%) | 56.0% | 25% |
|
| Growth | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 52.0% | 13.1% | 96% |
|
| Net Income (5yr) | (25.3%) | (10.1%) | 16% |
|
| EPS (5yr) | (14.9%) | 15.7% | 19 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.4%) | (15.6%) | 44% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 5 | 5 | |
| Current EPS | ($0.035) | ($0.062) | ($0.102) | |
| Month Ago EPS | ($0.035) | ($0.062) | ($0.102) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.030) | ($0.066) | ($0.090) | |
| Year/Year Chg | 16.7% | (77.5%) | (131.5%) | |
| Financials | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $13 | $37 | 10% |
|
| Net Income (TTM) (Mil) | ($32) | ($43) | 20% |
|
| EPS (TTM) | ($0.134) | ($1.500) | 35% |
|
| Operating Cash Flow (TTM) (Mil) | ($24) | ($32) | 14% |
|
| Net Cash Flow (TTM) (Mil) | ($5) | $2 | 34% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 18% |
|
| Enterprise Value (Q1) (Mil) | $221 | $177 | 27% |
|
| Valuation | LCTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.33 | 2.67 | 75% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | LCTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (57.4%) | 69.0% | 2% |
|
| Net Margin | (246.6%) | (71.5%) | 4% |
|
| ROA | (32.7%) | (47.4%) | 16% |
|
| ROE | (59.0%) | (54.6%) | 14% |
|
| Liabilities to Assets | 43.7% | 29.3% | 35% |
|
| F-Score | 4 | 3 | 33% |
|
Lineage Cell Therapeutics, Inc. did not pass any screens on 9/22/2026.
